Floatz logo

Rifaximin

Liver Cirrhosis

Post Graduate Institute of Medical Education and Research, ChandigarhSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
73/ 100

Competitive context

142 Active assets in the Liver Cirrhosis cohort.

Asset / SponsorPhaseRating
PARITAPREVIR
AbbVie
Phase 3A
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
NORMAL HUMAN SERUM ALBUMIN
King George's Medical University
Phase 4BBB
CHOLYL-LYSL-FLUORESCEIN
Norgine
Phase 3BBB

View all 50 →

Same molecule, other indications

Rifaximin is also rated in:

hepatic encephalopathyDormant
BBB
Indicative ·
75 / 100
View asset →
AscitesDormant
BB
Indicative ·
70 / 100
View asset →
hepatitis C virus infectionDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →